Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective, Multicenter, Randomized Trial of Neoadjuvant Capecitabine and Oxaliplatin (CAPOX) Plus Tislelizumab Versus CAPOX in Microsatellite Stable High-risk Locally Advanced Colon Cancer

NCT07132008 is registered in ClinicalTrials.gov with First Affiliated Hospital of Guangxi Medical University as lead sponsor.

NCT NCT07132008
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07132008 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective, Multicenter, Randomized Trial of Neoadjuvant Capecitabine and Oxaliplatin (CAPOX) Plus Tislelizumab Versus CAPOX in Microsatellite Stable High-risk Locally Advanced Colon Cancer
Lead sponsor
First Affiliated Hospital of Guangxi Medical University
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 1, 2025
Completion date
September 30, 2030
Enrollment
94 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colonic neoplasms, immune checkpoint inhibitors, neoadjuvant therapy